BLENREP is a humanized IgG1 kappa anti-BCMA monoclonal antibody conjugated to a microtubule inhibitor, mcMMAF^*

The target — BCMA

• BCMA is a cell surface protein present on multiple myeloma cells and normal B lymphocytes

BLENREP's mechanism of action is a two-part process:

1. Delivery of a cytotoxic agent (mcMMAF)
   • Upon binding BCMA on target cells, BLENREP is rapidly internalized and delivers mcMMAF
   • mcMMAF is a microtubule inhibitor that disrupts cellular function, leading to cell cycle arrest and apoptosis
2. Immune system activation
   • The belantamab antibody enhances recruitment and activation of immune effector cells, which kill by:
     1. Antibody-dependent cellular cytotoxicity (ADCC), and
     2. Phagocytosis of the cell
   • Apoptosis is accompanied by markers of immunogenic cell death, which may contribute to an adaptive immune response to the target cells